Welcome to our dedicated page for EVOMMUNE SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evommune, Inc. (NYSE: EVMN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. As a public company, Evommune submits reports to the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events.
Among these documents are current reports on Form 8-K, such as the filing in which Evommune reported issuing a press release with a business update and financial results for a completed quarter. That press release, furnished as an exhibit and incorporated by reference, summarized the status of its lead programs EVO756 and EVO301, clinical milestones, collaboration revenue and cash position. Similar filings can help readers understand how the company presents its pipeline and operations to regulators and investors.
On this page, users can review Evommune’s periodic and current reports, including items that address results of operations and financial condition, risk factor discussions and descriptions of forward-looking statements. These filings often elaborate on topics such as clinical trial design and timing, potential market opportunities for chronic inflammatory disease therapies, and risks related to regulatory approval, competition, intellectual property and collaborations.
Stock Titan enhances access to these SEC documents with AI-powered summaries that highlight key points from long filings, helping users quickly identify sections on clinical programs, financial metrics and material events. The page also updates as new filings are submitted to the SEC’s EDGAR system, allowing investors and researchers to follow Evommune’s regulatory history, including current reports, registration statements and other relevant disclosures.
Evommune, Inc. (EVMN) reported insider ownership changes tied to its initial public offering. RA Capital–affiliated entities converted Series C Preferred Stock into Common Stock immediately prior to the IPO and also bought additional shares in the offering.
The Fund and RA Capital Nexus Fund III converted preferred stock into 1,517,329 and 691,441 shares of Common Stock, respectively, and then purchased 1,157,096 and 92,904 additional Common shares at $16 per share. These holdings are reported as indirectly owned, with RA Capital Management, L.P., its general partner, and related individuals disclaiming beneficial ownership beyond their pecuniary interests. The reporting persons are identified as both a director affiliate and 10% owner of Evommune.
Evommune, Inc. insider LSP 7 Management B.V., as director of LSP 7 Cooperatief U.A., reported multiple equity transactions dated 11/07/2025. All outstanding shares of Series A, Series B, and Series C preferred stock automatically converted into common stock immediately before Evommune’s initial public offering, for no additional consideration, at fixed ratios for each series. Following these conversions, the reporting person bought an additional 1,562,500 shares of common stock at $16 per share. After the reported transactions, LSP 7 Cooperatief U.A. directly held 4,929,633 shares of Evommune common stock.